Skip to main content
OpenTrials
Completed

NCT Number: NCT04042454

To Assess the Safety and Tolerance of Infant Formula With Locust Bean Gum in Infants With Regurgitation

A randomized, controlled study to evaluate the safety and tolerance of an infant formula with locust bean gum in infants with regurgitation. (Solar)

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 week–9 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

A.O.U. Ospedali Riuniti di Ancona, Ancona, Italy

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Singleton infants with regurgitation who are otherwise healthy
  • Diagnosed with regurgitation according to the (adapted) Rome IV diagnostic criteria.
  • Term infants with a gestational age at birth of ≥37 weeks + 0 days and ≤41 weeks + 6 days
  • Aged > 3 weeks (21 days) and < 9 weeks (63 days) at screening
  • Exclusively formula fed for ≥ 7 days before screening
  • Written informed consent from the parent(s) and/or legally acceptable representative(s)

Exclusion criteria

  • Low birth weight for gestational age and gender
  • Infants diagnosed with or suspected to have gastroesophageal reflux disease (GERD). I
  • Infants who received any of the following medication within 4 weeks prior to screening: systemic antibiotics, prokinetics and/or proton pump inhibitors and/or (other) medication to treat regurgitation
  • Infants who already consumed a thickened anti-regurgitation (AR) formula or used thickening supplements
  • Infants who already started complementary feeding
  • Infants with a gastrointestinal infection within 4 weeks prior to screening
  • Infants with a congenital condition, previous or current illness, and/or medication use that could interfere with the main study outcomes according to the investigator
  • Infants known or suspected to have: allergy for fish, soy protein, soy oil or corn; lactose intolerance; galactosaemia including history of any other allergic manifestations or known allergy to any of the study product ingredients and/or requiring a fibre-free diet
  • Infants known or suspected to have allergy to cow's milk protein
  • Presence of any other gastrointestinal symptom(s)/disorder(s) that are not functional in nature, as assessed by the investigator's clinical judgement
  • Participation in any other studies involving investigational or marketed products concomitantly or prior to screening
  • Incapability of the parent(s) to comply with the study protocol or investigator's uncertainty about the willingness or ability of the parent(s) to comply with the protocol requirements

Treatment and study plan

milk based anti-regurgitation infant formula

Other

Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.

milk based infant formula

Other

Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.

Primary outcomes

  1. Average stool consistency

    Time frame: 8 weeks

    The average stool consistency (based on the 4-point Brussels Infant and Toddler Stool Scale [BITSS]) of the 8th week of intervention, adjusted for the baseline stool consistency score. Catagories are hard stools, formed stools, loose stools and watery stools. https://bitss-stoolscale.com/ (assessed 31-Jan-19) can be used as a further reference.

Secondary outcomes

  1. To assess the average stool consistency

    Time frame: 8 weeks

    The average stool consistency based on the BITSS, adjusted for baseline, for every week until the 8th week of intervention and for the week prior to the age of 17 weeks

  2. The average stool frequency

    Time frame: 8 weeks

    The average stool frequency, adjusted for baseline, for every week until and including the 8th week of intervention and for the week prior to the age of 17 weeks

  3. Incidence of diarrhoea:

    Time frame: 8 weeks, 17 weeks

    • based on the WHO criteria and derived from the BITSS, for every week (until and including week 8 of intervention, and at the age of 17 weeks)
    • based on investigator's diagnosis of diarrhoea (throughout the entire study)
  4. IGSQ sum and individual item scores

    Time frame: 2, 4, 8, 17 weeks

    IGSQ sum and individual item scores, adjusted for baseline, at 2, 4 and 8 weeks of intervention, and at the age of 17 weeks

  5. Gut microbiota composition and function

    Time frame: 17 weeks

    Gut microbiota composition and function (acetate, lactate, pH, calprotectin, ammonium and sIgA) at baseline and at the age of 17 weeks

  6. Regurgitation

    Time frame: 2,4,8,17 weeks

    Regurgitation: number of regurgitation episodes per day and the regurgitation volume score, adjusted for baseline, at 2, 4 and 8 weeks of intervention, and at the age of 17 weeks (based on 3-day diaries)

Sponsors and collaborators

Lead sponsor

Nutricia Research

Industry

Registry information

Official study title

A Randomized, Controlled Study to Evaluate the Safety and Tolerance of an Infant Formula With Locust Bean Gum in Infants With Regurgitation

Acronym: Solar

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Aug 2, 2019
Registry last updated
Jul 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.